|
N
|
7300
|
676
|
287
|
|
Age, median (IQR), years
|
58 (49, 66)
|
56 (46, 64)
|
56 (47, 65)
|
|
Female, n (%)
|
5667 (77.63)
|
539 (78.73)
|
233 (81.18)
|
|
Disease duration, median (IQR), years
|
5 (2, 12)
|
4 (1, 12)
|
5 (1, 12)
|
|
Seropositive*, n (%)
|
3783 (56.81)
|
303 (47.20)
|
131 (48.34)
|
|
Conventional DMARD use, n (%)
|
5994 (82.11)
|
521 (77.07)
|
200 (69.69)
|
|
Methotrexate
|
4873 (66.75)
|
414 (61.24)
|
149 (51.92)
|
|
Non-methotrexate csDMARDs
|
2414 (33.07)
|
232 (34.32)
|
95 (33.10)
|
|
Glucocorticoid use, any
|
2482 (34.00)
|
242 (35.80)
|
104 (36.24)
|
|
CDAI, median (IQR)**
|
15.6 (7.5, 25.8)
|
18.0 (9.9, 28.2)
|
18.4 (8.7, 28.0)
|
|
Remission, n (%)
|
642 (8.79)
|
36 (5.33)
|
16 (5.57)
|
|
Low disease activity, n (%)
|
1729 (23.68)
|
133 (19.67)
|
64 (22.30)
|
|
Moderate disease activity, n (%)
|
2362 (32.36)
|
226 (33.43)
|
86 (29.97)
|
|
High disease activity, n (%)
|
2298 (31.48)
|
265 (39.20)
|
113 (39.37)
|
|
HAQ, median (IQR)**
|
0.86 (0.25, 1.38)
|
1.00 (0.50, 1.63)
|
1.00 (0.50, 1.63)
|
|
Comorbidities, n (%)
|
|
Anemia
|
105 (1.44)
|
21 (3.11)
|
10 (3.48)
|
|
Asthma
|
113 (1.55)
|
9 (1.33)
|
5 (1.74)
|
|
Depression
|
317 (4.34)
|
38 (5.62)
|
17 (5.92)
|
|
Diabetes mellitus
|
279 (3.82)
|
30 (4.44)
|
12 (4.18)
|
|
Diarrhea
|
76 (1.04)
|
10 (1.48)
|
4 (1.39)
|
|
Dyspepsia
|
96 (1.32)
|
10 (1.48)
|
8 (2.79)
|
|
Fibromyalgia
|
111 (1.52)
|
18 (2.66)
|
8 (2.79)
|
|
Hepatic event
|
10 (0.14)
|
2 (0.30)
|
1 (0.35)
|
|
Hyperlipidemia
|
255 (3.49)
|
27 (3.99)
|
15 (5.23)
|
|
Hypertension
|
942 (12.90)
|
91 (13.46)
|
41 (14.29)
|
|
Nausea
|
86 (1.18)
|
9 (1.33)
|
4 (1.39)
|
|
Cancer
|
139 (1.90)
|
14 (2.07)
|
4 (1.39)
|
|
Stroke
|
61 (0.84)
|
7 (1.04)
|
4 (1.39)
|
|
Ulcer
|
188 (2.58)
|
21 (3.11)
|
12 (4.18)
|
|
Miscellaneous#
|
1313 (17.99)
|
98 (14.50)
|
43 (14.98)
|
